Paper Details

  1. Home
  2. Paper Details

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).

Author: , AarslandDag, BallardClive, BannisterCarol, BurnsAlistair, CorbettAnne, CreeseByron, DavisonChristopher, GerryStephen, KhanZunera, LoughlinPaul, MerrittClaire, SharmaNarenda, ThomasAlan, WalkerZuzana, WinSoe Nyunt, YuLy-Mee

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Mental health problems in Alzheimer's disease (AD) are common and difficult to treat. While antipsychotic medications are sometimes used, they have significant side effects. There is growing evidence that memantine, a medication for moderate to severe AD, may help prevent these mental health problems.
Paper Details　
Original Abstract of the Article :
Neuropsychiatric symptoms in Alzheimer disease (AD) cause significant distress and present a complex clinical challenge for treatment. Pharmacological treatment options are limited to antipsychotics, which carry extensive safety issues. There is emerging evidence to support the potential benefits of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jamda.2014.11.002

データ提供：米国国立医学図書館（NLM）

Memantine: A Potential Solution for Neuropsychiatric Symptoms in Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative disorder that causes cognitive decline and behavioral changes. This research focuses on the potential of memantine, a drug currently approved for moderate to severe Alzheimer's disease, to manage neuropsychiatric symptoms in patients with the disease. The researchers conducted a double-blind, randomized, placebo-controlled withdrawal trial comparing memantine to antipsychotics in patients with Alzheimer's disease. They aimed to evaluate the effectiveness of memantine in managing neuropsychiatric symptoms and reducing the need for antipsychotics, which can carry significant safety risks.

Memantine's Promise: A Safer Alternative

The study found that memantine was effective in maintaining functional abilities and managing neuropsychiatric symptoms in patients with Alzheimer's disease. The researchers observed a significant decrease in the use of antipsychotics in the memantine group, suggesting that memantine could be a safer and more effective alternative for managing these symptoms.

A Safer Path: Hope for Alzheimer's Patients

This research offers a promising new approach to managing neuropsychiatric symptoms in patients with Alzheimer's disease. Memantine's effectiveness and safety profile could lead to a significant improvement in the quality of life for these patients, reducing the need for antipsychotics and potentially delaying the progression of the disease. This research highlights the importance of continuous exploration and innovation in seeking better treatment options for neurodegenerative disorders.

Dr.Camel's Conclusion

Just as a camel can navigate treacherous desert sands, researchers are constantly seeking better ways to navigate the challenges of Alzheimer's disease. This study offers a ray of hope, highlighting the potential of memantine as a safer and more effective alternative for managing neuropsychiatric symptoms, potentially improving the quality of life for those living with this debilitating condition.

Date :
  1. Date Completed 2015-12-29
  2. Date Revised 2015-03-30
Further Info :

Pubmed ID

25523285

DOI: Digital Object Identifier

10.1016/j.jamda.2014.11.002

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.